PubRank

Scott A Armstrong

Author PubWeight™ 174.75‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006 25.99
2 High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007 12.68
3 FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007 12.33
4 Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature 2006 11.90
5 Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 2006 10.29
6 MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer 2007 8.17
7 H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 2008 5.23
8 Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011 4.90
9 MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011 4.56
10 The Wnt/beta-catenin pathway is required for the development of leukemia stem cells in AML. Science 2010 4.37
11 Chromatin-modifying enzymes as modulators of reprogramming. Nature 2012 4.22
12 Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance. Cancer Cell 2006 3.93
13 HOXA9 is required for survival in human MLL-rearranged acute leukemias. Blood 2008 3.12
14 Genetic and pharmacologic inhibition of β-catenin targets imatinib-resistant leukemia stem cells in CML. Cell Stem Cell 2012 2.89
15 AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell 2011 2.77
16 Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood 2003 2.35
17 BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia. Blood 2007 2.12
18 mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. Cell Stem Cell 2012 2.06
19 Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease. EMBO J 2005 1.79
20 Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med 2013 1.71
21 Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009 1.61
22 Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A 2012 1.52
23 Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 2013 1.46
24 In Vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell 2013 1.42
25 Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. Blood 2013 1.38
26 Differential niche and Wnt requirements during acute myeloid leukemia progression. Blood 2011 1.32
27 Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 2002 1.30
28 Haploinsufficiency of Dnmt1 impairs leukemia stem cell function through derepression of bivalent chromatin domains. Genes Dev 2012 1.26
29 Common and overlapping oncogenic pathways contribute to the evolution of acute myeloid leukemias. Cancer Res 2011 1.23
30 Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 2005 1.20
31 The Stem Cell Discovery Engine: an integrated repository and analysis system for cancer stem cell comparisons. Nucleic Acids Res 2011 1.18
32 Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells. Blood 2007 1.18
33 Self-renewal related signaling in myeloid leukemia stem cells. Int J Hematol 2011 1.17
34 Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. Trends Immunol 2012 1.15
35 miR-128b is a potent glucocorticoid sensitizer in MLL-AF4 acute lymphocytic leukemia cells and exerts cooperative effects with miR-221. Blood 2009 1.11
36 iCanPlot: visual exploration of high-throughput omics data using interactive Canvas plotting. PLoS One 2012 1.10
37 Targeting epigenetic programs in MLL-rearranged leukemias. Hematology Am Soc Hematol Educ Program 2011 1.08
38 Recent progress toward epigenetic therapies: the example of mixed lineage leukemia. Blood 2013 1.08
39 Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia. Blood 2009 1.05
40 A role for DOT1L in MLL-rearranged leukemias. Epigenomics 2011 1.02
41 EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 2012 1.01
42 FLT3 as a therapeutic target in childhood acute leukemia. Curr Drug Targets 2007 1.00
43 A novel mutation in the miR-128b gene reduces miRNA processing and leads to glucocorticoid resistance of MLL-AF4 acute lymphocytic leukemia cells. Cell Cycle 2010 0.99
44 Targeting epigenetic regulators for cancer therapy. Ann N Y Acad Sci 2014 0.95
45 NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant 2010 0.95
46 Cancer: inappropriate expression of stem cell programs? Cell Stem Cell 2008 0.92
47 Mixed lineage leukemia translocations and a leukemia stem cell program. Cancer Res 2007 0.92
48 Leukemia stem cells and human acute lymphoblastic leukemia. Semin Hematol 2009 0.92
49 Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia. Cancer Res 2005 0.91
50 Linking miRNA regulation to BCR-ABL expression: the next dimension. Cancer Cell 2008 0.91
51 The cell fate determinant Llgl1 influences HSC fitness and prognosis in AML. J Exp Med 2012 0.90
52 eXframe: reusable framework for storage, analysis and visualization of genomics experiments. BMC Bioinformatics 2011 0.89
53 Gene expression profiling of leukemia stem cells. Methods Mol Biol 2009 0.89
54 DNA methylation profiling in acute myeloid leukemia: from recent technological advances to biological and clinical insights. Future Oncol 2010 0.87
55 Crebbp haploinsufficiency in mice alters the bone marrow microenvironment, leading to loss of stem cells and excessive myelopoiesis. Blood 2011 0.86
56 Therapeutic implications of leukemia stem cell development. Clin Cancer Res 2007 0.85
57 Erratum: Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies. Sci Data 2014 0.83
58 HELP for AML: methylation profiling opens new avenues. Cancer Cell 2010 0.83
59 Transformation from committed progenitor to leukemia stem cells. Ann N Y Acad Sci 2009 0.83
60 Cancer stem cells in hematopoietic malignancies. Biol Blood Marrow Transplant 2008 0.82
61 MLL-rearranged B lymphoblastic leukemias selectively express the immunoregulatory carbohydrate-binding protein galectin-1. Clin Cancer Res 2010 0.82
62 MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 2016 0.80
63 Genome-wide SNP analysis in cancer: leukemia shows the way. Cancer Cell 2007 0.80
64 Cancer: The flipside of Notch. Nature 2011 0.79
65 MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. J Clin Invest 2016 0.78
66 Genetics, epigenetics, and leukemia. N Engl J Med 2010 0.78
67 Cancer Stem Cells in Hematopoietic Malignancies. Biol Blood Marrow Transplant 2008 0.77
68 DOT1L-mediated H3K79 methylation in chromatin is dispensable for Wnt pathway-specific and other intestinal epithelial functions. Mol Cell Biol 2013 0.77
69 Erratum: Modulation of splicing catalysis for therapeutic targeting of leukemia with mutations in genes encoding spliceosomal proteins. Nat Med 2016 0.76
70 Microarrays to identify new therapeutic strategies for cancer. Adv Cancer Res 2007 0.76
71 Cancer. Can one cell influence cancer heterogeneity? Science 2012 0.76
72 AACR Cancer Progress Report 2016. Clin Cancer Res 2016 0.75
73 Stem cells: Dual response to Ras mutation. Nature 2013 0.75
74 Erratum: PGBD5 promotes site-specific oncogenic mutations in human tumors. Nat Genet 2017 0.75
75 Distinctive IGH gene segment usage and minimal residual disease detection in infant acute lymphoblastic leukaemias. Br J Haematol 2005 0.75